| Entry |
|
|---|
| Name |
Fluvoxamine maleate (JP18/USP);
Luvox (TN) |
|---|
| Product |
|
|---|
| Generic |
FLUVOXAMINE MALEATE (A-S Medication Solutions), FLUVOXAMINE MALEATE (ANI Pharmaceuticals), FLUVOXAMINE MALEATE (Actavis Pharma), FLUVOXAMINE MALEATE (Ajanta Pharma USA), FLUVOXAMINE MALEATE (Apotex Corp), FLUVOXAMINE MALEATE (Bionpharma), FLUVOXAMINE MALEATE (Bionpharma), FLUVOXAMINE MALEATE (Bionpharma), FLUVOXAMINE MALEATE (Bryant Ranch Prepack), FLUVOXAMINE MALEATE (Bryant Ranch Prepack), FLUVOXAMINE MALEATE (Bryant Ranch Prepack), FLUVOXAMINE MALEATE (Bryant Ranch Prepack), FLUVOXAMINE MALEATE (Chartwell RX), FLUVOXAMINE MALEATE (Endo USA), FLUVOXAMINE MALEATE (PD-Rx Pharmaceuticals), FLUVOXAMINE MALEATE (Preferred Pharmaceuticals), FLUVOXAMINE MALEATE (Preferred Pharmaceuticals), FLUVOXAMINE MALEATE (REMEDYREPACK), FLUVOXAMINE MALEATE (REMEDYREPACK), FLUVOXAMINE MALEATE (REMEDYREPACK), FLUVOXAMINE MALEATE (Upsher-Smith Laboratories) |
|---|
| Formula |
C15H21F3N2O2. C4H4O4
|
|---|
| Exact mass |
434.1665
|
|---|
| Mol weight |
434.41
|
|---|
| Structure |
|
|---|
| Class |
Neuropsychiatric agent
DG01659 Selective serotonin reuptake inhibitor (SSRI)
Metabolizing enzyme substrate
DG01644 CYP2D6 substrate
Metabolizing enzyme inhibitor
DG01634 CYP1A2 inhibitor
DG01643 CYP2C9 inhibitor
DG01933 CYP2C19 inhibitor
DG01645 CYP2D6 inhibitor
DG02852 CYP3A/CYP3A4 inhibitor
DG01522 CYP3A4 inhibitor
|
|---|
| Remark |
| Therapeutic category: | 1179 |
| Product (DG00946): | D00824<JP/US> |
|
|---|
| Efficacy |
Antidepressant, Selective serotonin reuptake inhibitor (SSRI) |
|---|
| Disease |
Obsessive compulsive disorder [DS: H01450] |
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Metabolism |
Enzyme: CYP2D6 [HSA: 1565]
|
|---|
| Interaction |
CYP inhibition: CYP1A2 [HSA: 1544], CYP2C19 [HSA: 1557]; CYP2C9 [HSA: 1559], CYP2D6 [HSA: 1565], CYP3A4 [HSA: 1576]
|
|---|
| Structure map |
| map07234 | Neurotransmitter transporter inhibitors |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N06 PSYCHOANALEPTICS
N06A ANTIDEPRESSANTS
N06AB Selective serotonin reuptake inhibitors
N06AB08 Fluvoxamine
D00824 Fluvoxamine maleate (JP18/USP) <JP/US>
USP drug classification [BR:br08302]
Antidepressants
SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/Serotonin and Norepinephrine Reuptake Inhibitors)
Fluvoxamine
D00824 Fluvoxamine maleate (JP18/USP)
Therapeutic category of drugs in Japan [BR:br08301]
1 Agents affecting nervous system and sensory organs
11 Agents affecting central nervous system
117 Psychotropics
1179 Others
D00824 Fluvoxamine maleate (JP18/USP)
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01659 Selective serotonin reuptake inhibitor (SSRI)
DG00946 Fluvoxamine
D00824 Fluvoxamine maleate
Metabolizing enzyme substrate
DG01644 CYP2D6 substrate
DG00946 Fluvoxamine
D00824 Fluvoxamine maleate
Metabolizing enzyme inhibitor
DG01634 CYP1A2 inhibitor
DG00946 Fluvoxamine
D00824 Fluvoxamine maleate
DG01643 CYP2C9 inhibitor
DG00946 Fluvoxamine
D00824 Fluvoxamine maleate
DG01933 CYP2C19 inhibitor
DG00946 Fluvoxamine
D00824 Fluvoxamine maleate
DG01645 CYP2D6 inhibitor
DG00946 Fluvoxamine
D00824 Fluvoxamine maleate
DG02852 CYP3A/CYP3A4 inhibitor
DG01522 CYP3A4 inhibitor
DG00946 Fluvoxamine
D00824 Fluvoxamine maleate
Drug classes [BR:br08332]
Neuropsychiatric agent
DG01659 Selective serotonin reuptake inhibitor (SSRI)
D00824 Fluvoxamine maleate
Target-based classification of drugs [BR:br08310]
Transporters
Solute carrier family
SLC6
SLC6A4 (HTT)
D00824 Fluvoxamine maleate (JP18/USP) <JP/US>
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
D00824 Fluvoxamine maleate
D00824 Fluvoxamine maleate tablets
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D00824
Pharmacogenomic biomarkers [br08341.html]
Polymorphisms and mutations affecting drug response
D00824
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01659 Selective serotonin reuptake inhibitor (SSRI)
DG00946 Fluvoxamine
Metabolizing enzyme substrate
DG01644 CYP2D6 substrate
DG00946 Fluvoxamine
Metabolizing enzyme inhibitor
DG01634 CYP1A2 inhibitor
DG00946 Fluvoxamine
DG01643 CYP2C9 inhibitor
DG00946 Fluvoxamine
DG01933 CYP2C19 inhibitor
DG00946 Fluvoxamine
DG01645 CYP2D6 inhibitor
DG00946 Fluvoxamine
DG02852 CYP3A/CYP3A4 inhibitor
DG01522 CYP3A4 inhibitor
DG00946 Fluvoxamine
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 30
1 C2b C 39.7600 -15.4000
2 C2b C 41.4400 -15.4000
3 C6a C 39.0600 -16.5900
4 C6a C 42.1400 -16.5900
5 O6a O 37.6600 -16.5900
6 O6a O 39.7600 -17.7800
7 O6a O 41.4400 -17.7800
8 O6a O 43.5400 -16.5900
9 C8y C 23.5900 -14.4900
10 C8x C 23.5900 -15.8900
11 C8x C 24.7800 -16.5900
12 C8y C 26.0400 -15.8900
13 C8x C 26.0400 -14.4900
14 C8x C 24.7800 -13.7900
15 C1d C 22.4000 -13.7900
16 X F 21.1400 -13.0900
17 X F 23.0300 -12.5300
18 X F 21.7700 -15.0500
19 C2c C 27.2300 -16.5900
20 C1b C 28.4900 -15.8900
21 N2b N 27.2300 -17.9900
22 O2a O 28.4900 -18.6900
23 C1b C 29.6800 -17.9900
24 C1b C 30.8700 -18.6900
25 N1a N 32.0600 -17.9900
26 C1b C 29.6100 -16.5900
27 C1b C 30.8700 -15.8900
28 C1b C 32.0600 -16.5900
29 O2a O 33.2500 -15.8900
30 C1a C 34.4400 -16.5900
BOND 29
1 1 2 2
2 1 3 1
3 2 4 1
4 3 5 1
5 3 6 2
6 4 7 1
7 4 8 2
8 9 10 2
9 10 11 1
10 11 12 2
11 12 13 1
12 13 14 2
13 9 14 1
14 9 15 1
15 15 16 1
16 15 17 1
17 15 18 1
18 12 19 1
19 19 20 1
20 19 21 2
21 21 22 1
22 22 23 1
23 23 24 1
24 24 25 1
25 20 26 1
26 26 27 1
27 27 28 1
28 28 29 1
29 29 30 1
|
|---|
